Value of FDG Positron Emission Tomography in Monitoring the Effects of Therapy in Progressive Pulmonary Sarcoidosis
- 1 February 2007
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 32 (2) , 114-116
- https://doi.org/10.1097/01.rlu.0000252216.68848.d7
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Combined C-11 Methionine and F-18 FDG PET Imaging in a Case of NeurosarcoidosisClinical Nuclear Medicine, 2006
- Differentiation Between Carcinoid and Sarcoid With F-18 FDG PET and In-111 PentetreotideClinical Nuclear Medicine, 2006
- Vertebral Sarcoidosis Mimicking Lytic Osseous MetastasesJCR: Journal of Clinical Rheumatology, 2005
- Sarcoidosis Demonstrated by FDG PET Imaging With Negative Findings on Gallium ScintigraphyClinical Nuclear Medicine, 2005
- Fluorodeoxyglucose PET Scan in Pulmonary Sarcoidosis during Treatment with Inhaled and Oral CorticosteroidsRespiration, 2003
- The role of positron emission tomography with 18 F-fluoro-2-deoxy-D-glucose in respiratory oncologyEuropean Respiratory Journal, 2001
- High Fluorine-18 Labeled Deoxyglucose Uptake in SarcoidosisClinical Nuclear Medicine, 1996
- Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1994